Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics. Cancer J Clin. 2021;71:7–33.

Article  Google Scholar 

Sasaki T, Kanata R, Yamada I, Matsuyama M, Ozaka M, Sasahira N. Improvement of treatment outcomes for metastatic pancreatic cancer: a real-world data analysis. In Vivo. 2019;33:271–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ilic M, Ilic I. Epidemiology of pancreatic cancer. World J Gastroenterol: WJG. 2016;22:9694–705.

Article  PubMed  PubMed Central  Google Scholar 

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.

Article  CAS  PubMed  Google Scholar 

Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.

Article  Google Scholar 

Tempero MA, Malafa MP, Al-Hawary M, Behrman SW, Benson AB, Cardin DB, et al. Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19:439–57.

Article  CAS  PubMed  Google Scholar 

Williet N, Saint A, Pointet AL, Tougeron D, Pernot S, Pozet A, et al. Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study. Ther Adv Gastroenterol. 2019;12:1756284819878660.

Article  Google Scholar 

Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, et al. Comparative effectiveness of nab-paclitaxel plus gemcitabine vs FOLFIRINOX in metastatic pancreatic cancer: a retrospective nationwide chart review in the United States. Adv Ther. 2018;35:1564–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Muranaka T, Kuwatani M, Komatsu Y, Sawada K, Nakatsumi H, Kawamoto Y, et al. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. J Gastrointest Oncol. 2017;8:566–71.

Article  PubMed  PubMed Central  Google Scholar 

Sawada M, Kasuga A, Mie T, Furukawa T, Taniguchi T, Fukuda K, et al. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer. BMC Cancer. 2020;20:449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545–57.

Article  CAS  PubMed  Google Scholar 

Nakai Y, Isayama H, Sasaki T, Sasahira N, Tsujino T, Toda N, et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. Br J Cancer. 2012;106:1934–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640–8.

Article  CAS  PubMed  Google Scholar 

Saito K, Nakai Y, Takahara N, Ishigaki K, Suzuki Y, Inokuma A, et al. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Invest New Drugs. 2021;39:605–13.

Article  CAS  PubMed  Google Scholar 

Kawamoto Y, Nakatsumi H, Harada K, Muranaka T, Ishiguro A, Kobayashi Y, et al. A Phase I Trial of oxaliplatin, irinotecan, and S-1 combination therapy (OX-IRIS) as chemotherapy for unresectable pancreatic cancer (HGCSG 1403). Oncologist. 2021;26:e1675–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yanagimoto H, Satoi S, Sho M, Akahori T, Yamamoto T, Hirooka S, et al. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2016;77:35–41.

Article  CAS  PubMed  Google Scholar 

Akahori T, Sho M, Yanagimoto H, Satoi S, Nagai M, Nishiwada S, et al. Phase II Study Of The Triple Combination Chemotherapy of SOXIRI (S-1/Oxaliplatin/Irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma. Oncologist. 2019;24:749-e224.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohba A, Ueno H, Shiba S, Okano N, Kobayashi T, Nagashima F, et al. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-escalation and dose-expansion clinical trial. Eur J Cancer. 2022;174:40–7.

Article  CAS  PubMed  Google Scholar 

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

Article  CAS  PubMed  Google Scholar 

Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.

Article  CAS  PubMed  PubMed Central  Google Scholar